Edgewise Therapeutics (EWTX) Stock Forecast, Price & News

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Edgewise Therapeutics in the last year. There are currently 1 sell rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" EWTX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in EWTX, but not buy additional shares or sell existing shares.
View EWTX analyst ratings or view top-rated stocks.

3 analysts have issued twelve-month price targets for Edgewise Therapeutics' stock. Their EWTX share price forecasts range from $5.00 to $29.00. On average, they predict the company's stock price to reach $17.00 in the next twelve months. This suggests a possible upside of 78.8% from the stock's current price.
View analysts price targets for EWTX or view top-rated stocks among Wall Street analysts.

Edgewise Therapeutics' stock was trading at $8.94 at the start of the year. Since then, EWTX stock has increased by 6.4% and is now trading at $9.51.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our EWTX earnings forecast.

Edgewise Therapeutics, Inc. (NASDAQ:EWTX) posted its earnings results on Wednesday, November, 10th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by $0.05.

ETFs with the largest weight of Edgewise Therapeutics (NASDAQ:EWTX) stock in their portfolio include Virtus LifeSci Biotech Clinical Trials ETF (BBC), iShares Neuroscience and Healthcare ETF (IBRN), ALPS Medical Breakthroughs ETF (SBIO), Principal Healthcare Innovators ETF (BTEC), Invesco Nasdaq Biotechnology ETF (IBBQ), iShares Biotechnology ETF (IBB), ProShares Ultra Nasdaq Biotechnology (BIB) and

(EWTX) raised $150 million in an initial public offering on Friday, March 26th 2021. The company issued 10,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs, SVB Leerink and Wedbush PacGrow acted as the underwriters for the IPO.

Edgewise Therapeutics trades on the NASDAQ under the ticker symbol "EWTX."

Edgewise Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include FMR LLC (12.55%), BlackRock Inc. (4.54%), Geode Capital Management LLC (1.23%), Granahan Investment Management LLC (1.16%), State Street Corp (1.04%) and American Century Companies Inc. (0.80%). Insiders that own company stock include Alan J Russell, Behrad Derakhshan, Holdings A/S Novo, James E Flynn, Joanne M Donovan, John R Moore, Jonathan D Root, Kevin Koch, Orbimed Advisors Llc, Peter A Thompson and R Michael Carruthers.
View institutional ownership trends.

Shares of EWTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of EWTX stock can currently be purchased for approximately $9.51.

Edgewise Therapeutics (NASDAQ:EWTX) has a market capitalization of $601.78 million. The company earns $-67,640,000.00 in net income (profit) each year or ($1.33) on an earnings per share basis.

Edgewise Therapeutics' mailing address is 3415 COLORADO AVE., BOULDER CO, 80303. The official website for the company is www.edgewisetx.com. The company can be reached via phone at 720-262-7002 or via email at ir@edgewisetx.com.